Sung, Yen-LingYen-LingSungTING TSE LINSyu, Jhen-YangJhen-YangSyuHsu, Hung-JuiHung-JuiHsuLin, Kai-YuanKai-YuanLinYEN BIN LIULin, Shien-FongShien-FongLin2023-04-132023-04-132020-122055-5822https://scholars.lib.ntu.edu.tw/handle/123456789/630184Hypertension is a significant risk for the development of left ventricular hypertrophy, diastolic dysfunction, followed by heart failure and sudden cardiac death. While therapy with sacubitril/valsartan (SV) reduces the risk of sudden cardiac death in patients with heart failure and systolic dysfunction, the effect on those with diastolic dysfunction remains unclear. We hypothesized that, in the animal model of hypertensive heart disease, treatment with SV reduces the susceptibility to ventricular arrhythmia.enCardiac bridging integrator-1diastolic dysfunctionhypertensive heart diseaseSacubitril/valsartanSmall-conductance Ca2+-activated potassium channel type 2Ventricular arrhythmogenesis[SDGs]SDG3journal article10.1002/ehf2.13013329691912-s2.0-85091346681WOS:000572124200001